Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Comparison of VxWave and Standard Ultrasound Measurements of Blood Vessels in the Arm

29. oktober 2026 oppdatert av: Vexev Pty Ltd

The VxWave Ultrasound Imaging System Upper Limb Clinical Performance Trial

This study compares blood-vessel measurements obtained with the VxWave Ultrasound Imaging System and a standard ultrasound system operated by a qualified sonographer. Adults aged 21 years or older undergo scanning of the same arm with both systems at one study visit. The researchers compare vessel diameter and blood-flow velocity at three specified locations in the upper arm and forearm. They also assess scan completion, scanning time, participant comfort, device deficiencies and adverse events. A subset undergoes a repeat standard ultrasound scan to assess the repeatability of the reference measurements.

Studieoversikt

Detaljert beskrivelse

This is an interventional, single-cohort, within-participant paired method-comparison study. Every participant undergoes VxWave scanning first, followed by Philips Lumify scanning of the same arm by a qualified vascular sonographer in a separate room. Three locations are examined: the brachial artery immediately proximal and immediately distal to the midpoint between the elbow crease and axillary fold, and the radial artery at the midpoint between the radial styloid process and elbow crease.

A qualified vascular sonographer who did not acquire the images performs all measurements offline using OsiriX MD for Lumify images and VxView for VxWave images. Random dataset identifiers conceal participant identity, pairing and repeat status. Measurements from the corresponding other-system dataset are unavailable during review. Imaging-system identity is not concealed by the use of separate software platforms.

The first 20 consecutive participants after Participant ID 030 who complete comparator acquisition undergo one repeat comparator scan after probe and gel removal and at least two minutes of rest. The first comparator acquisition remains the reference for primary agreement analysis; repeat acquisition is used only for reference-pathway repeatability.

Enrollment stops upon reaching either 50 participants with successful unilateral scans in the per-protocol set or 85 participants in the full analysis set. The first unilateral visit supplies the primary participant record. Optional contralateral-arm visits provide exploratory observations. No routine follow-up visit is scheduled; any adverse event is followed until resolution or 60 days, whichever occurs first.

Participants may provide consent and enroll at Prince of Wales Private or remotely. All ultrasound scanning and study imaging data acquisition are performed at Vexev Pty Ltd, Suite 501, 78 Kippax Street, Surry Hills NSW 2010. The Prince of Wales Private location is used for recruitment, consent and enrollment only; no scanning or imaging data acquisition takes place there.

Studietype

Intervensjonell

Registrering (Antatt)

85

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Prince of Wales Private, A/Prof Shannon Thomas's Rooms (Recruitment and Enrollment Only)
        • Ta kontakt med:
      • Surry Hills, New South Wales, Australia, 2010
        • Vexev Pty Ltd
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 21 years or older and able to provide written informed consent.
  • Complete upper limb(s).

Exclusion Criteria:

  • Unable to provide informed consent.
  • Unable or unwilling to place the limb onto the VxWave scanning bed.
  • Infection risk to site staff and/or other study participants.
  • Open or healing wound on the study limb.
  • Known abnormal upper-limb vascular anatomy that would make scanning at the protocol discrete locations infeasible.
  • Known allergy to parabens present in standard ultrasound gels.
  • Any other reason at the discretion of the Principal Investigator.
  • Previous upper-limb vascular surgery.
  • Highly dependent on medical care.
  • Cognitive impairment or intellectual disability.

Vascular-anatomy and prior-surgery exclusions are assessed using self-reported history; review of medical records is not required for this assessment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: VxWave and Comparator Ultrasound

All participants undergo VxWave scanning followed by Philips Lumify scanning of the same arm during one study visit. The first 20 consecutive participants after Participant ID 030 who complete comparator acquisition also undergo a repeat Lumify scan after probe lift-off and at least two minutes of rest.

Robotically controlled acquisition of duplex B-mode and Doppler ultrasound data of the upper-limb vasculature, excluding the hand. The participant rests the limb on the scan bed while the probe moves beneath it. Images are measured offline using VxView. VxWave scanning occurs before the comparator scan.

Qualified vascular-sonographer acquisition of ultrasound data from the same upper-limb vascular locations after VxWave scanning. Images are measured offline using OsiriX MD. The specified repeatability subset undergoes a separate repeat comparator acquisition after probe lift-off and at least two minutes of rest.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Inter-System Agreement in Arterial Diameter
Tidsramme: During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Mean bias and 95% limits of agreement for VxWave minus comparator arterial diameter in millimetres at three pre-specified brachial/radial artery locations. Each location uses the mean of three diameter measurements. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. The +/-0.5 mm margin is a descriptive benchmark and does not define a binary study-success criterion. Only diagnostic-quality measurements are included in agreement analysis.

During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).
Inter-System Agreement in Peak Systolic Velocity
Tidsramme: During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Mean percentage bias and 95% limits of agreement in symmetric relative percentage differences between VxWave and comparator peak systolic velocity at the three pre-specified brachial/radial artery locations. Mean of three representative peak systolic velocity measurements per location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. Absolute-scale agreement in cm/s is a sensitivity analysis. No PSV acceptance criterion is specified. Only diagnostic-quality measurements are included.

During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Successful VxWave Scan Completion
Tidsramme: During the VxWave scan at the first study visit (Day 1).

Percentage of participants for whom VxWave completes the peripheral vascular imaging examination, with scan data judged by the reporting sonographer to be of diagnostic quality for measurement and able to confirm measurements. Reasons for failure include inability to perform both B-mode and Doppler measurements at two of the three discrete locations, or failure to complete scan data acquisition within a reasonable time (less than 55 minutes).

During the VxWave scan at the first study visit (Day 1).
Time Required to Complete VxWave Scanning
Tidsramme: During the VxWave scan at the first study visit (Day 1).

Elapsed time in minutes from initiation of the first acquisition run on the VxWave console to scan status complete on the final acquisition run, including time between runs. A scan may contain more than one acquisition run, including restarts after participant repositioning.

During the VxWave scan at the first study visit (Day 1).
Participant Comfort and Satisfaction With VxWave Scanning
Tidsramme: Immediately after the VxWave scan during the first study visit (Day 1).

Four questionnaire items assess overall comfort, satisfaction with scanning time, satisfaction with audible noise and overall satisfaction. Each item has five ordered response categories: Excellent, Very good, Good, Fair and Poor, with Excellent representing the most favorable response. Ordinal responses will be summarised using median/interquartile range or proportions. No composite score is specified in the protocol or supplied assessment form.

Immediately after the VxWave scan during the first study visit (Day 1).
Repeatability of Comparator Arterial Diameter Measurements
Tidsramme: During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

For the first 20 consecutive participants after Participant ID 030 who complete comparator acquisition, assess mean difference (bias), 95% limits of agreement and repeatability coefficient between first and repeat comparator arterial diameter measurements in millimetres at each pre-specified location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. The first comparator acquisition remains the reference for the primary endpoint; repeat acquisition is used for this secondary endpoint only.

During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.
Repeatability of Comparator Peak Systolic Velocity Measurements
Tidsramme: During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

For the same 20-participant repeatability cohort, assess mean difference (bias), 95% limits of agreement and repeatability coefficient between first and repeat comparator peak systolic velocity measurements, expressed as symmetric relative percentage differences, at each pre-specified location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals. This descriptive endpoint characterises reference-pathway repeatability and does not define an acceptance test.

During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Scanned Participants With at Least One Device Deficiency
Tidsramme: During the study scanning visit (Day 1).

100 multiplied by the number of unique scanned participants whose scan is associated with at least one VxWave device deficiency, divided by the total number of unique participants who undergo a scan. Include attempted scans regardless of successful completion or diagnostic image quality. Each participant is counted once, even if more than one deficiency or scan occurs. Device deficiencies include those identified before scan completion.

During the study scanning visit (Day 1).
Percentage of Scanned Participants With at Least One Adverse Event
Tidsramme: During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

100 multiplied by the number of unique scanned participants who experience at least one adverse event (AE), divided by the total number of unique participants who undergo a scan. AEs are counted regardless of their relationship to the device or study procedure. Include attempted scans regardless of successful completion. Each participant is counted once, even if multiple AEs or scans occur. Device/procedure-related AEs are included in this overall AE measure and are also reported separately as adverse device effects.

During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.
Percentage of Scanned Participants With at Least One Adverse Device Effect
Tidsramme: During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

100 multiplied by the number of unique scanned participants who experience at least one adverse device effect (ADE), divided by the total number of unique participants who undergo a scan. Per the protocol, an ADE is an AE related to the VxWave Ultrasound Imaging System or study procedure. Include attempted scans regardless of successful completion. Each participant is counted once, even if multiple ADEs or scans occur. ADEs are a subset of all AEs; the overall AE percentage and ADE percentage must not be added together.

During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Tam Nguyen, Vexev Pty Ltd

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

15. november 2026

Primær fullføring (Antatt)

15. januar 2027

Studiet fullført (Antatt)

20. januar 2027

Datoer for studieregistrering

Først innsendt

29. oktober 2026

Først innsendt som oppfylte QC-kriteriene

29. oktober 2026

Først lagt ut (Faktiske)

4. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CIP-2

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Individual participant data will be shared on request.

Tilgangskriterier for IPD-deling

On request.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere